Innovative Biomarkers and Imaging Techniques for the Early Detection and Risk Stratification of Uro-Oncological Tumours
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Epidemiology and Prevention".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 2
Special Issue Editor
2. Head of Department, Junior Clinical Cooperation Unit ‘Multiparametric Methods for the Early Detection of Prostate Cancer’, German Cancer Research Center (DKFZ), Heidelberg, Germany
Interests: artificial intelligence; early detection; multi-omics; precision medicine; surgery; uro-oncology
Special Issue Information
Dear Colleagues,
The early detection and risk stratification of uro-oncology tumours are being driven by novel biomarkers and advanced imaging techniques. These innovations are transforming the diagnosis and management of uro-oncological tumours, providing deeper insights into disease mechanisms and enabling more precise and personalized treatment strategies.
We are pleased to invite you to contribute to this Special Issue, entitled "Innovative Biomarkers and Imaging Techniques for the Early Detection and Risk Stratification of Uro-oncological Tumours". This Special Issue aims to provide a detailed exploration of the current landscape and future directions in the early detection and risk stratification of uro-oncological tumours, focusing on the integration of novel diagnostic technologies and their impact on clinical outcomes.
In this Special Issue, original research articles and reviews are welcome to be submitted. Research areas may include novel biomarkers in blood, urine, and tissue with significant potential for clinical application, providing a benefit for the early detection, prognosis, and risk stratification of uro-oncological tumours. In addition, we invite manuscripts that address the potential, challenges, and future prospects of incorporating advanced imaging techniques in uro-oncology. This includes the exploration of multimodal imaging approaches and their synergy with novel biomarkers to improve diagnostic accuracy and patient management.
Manuscripts that explore the integration of these novel biomarkers and imaging modalities into clinical workflows and their potential to improve patient stratification and therapeutic decision making are particularly encouraged.
I look forward to receiving your contributions.
Dr. Magdalena Görtz
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- uro-oncological tumours
- novel biomarkers
- advanced imaging techniques
- early detection
- risk stratification
- molecular diagnostics
- multimodal data integration
- personalized treatment
